Active Ingredient History

  • Now
Faldaprevir was an experimental drug for the treatment of hepatitis C (HCV). It was being developed by Boehringer-Ingelheim and reached Phase III clinical trials in 2011. Boehringer announced in 2014 that it would not pursue approval of the drug any more because of better HCV treatments having become available.   Wikipedia

  • SMILES: COc1ccc2c(O[C@@H]3C[C@H](N(C3)C(=O)[C@@H](NC(=O)OC4CCCC4)C(C)(C)C)C(=O)N[C@@]5(C[C@H]5C=C)C(=O)O)cc(nc2c1Br)c6csc(NC(=O)C(C)C)n6
  • Mol. Mass: 869.84
  • ALogP: 6.3
  • ChEMBL Molecule:
More Chemistry
bi201335 | bi 201335 | bi-201335 | faldaprevir | faldeprevir | n-((cyclopentyloxy)carbonyl)-3-methylvalyl-4-((8-bromo-7-methoxy-2-(2-((2-methylpropanoyl)amino)-1,3-thiazol-4-yl)quinolin-4-yl)oxy)-n-(1-carboxy-2-ethenylcyclopropyl)prolinamide


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue